Dr Noha Sharafeldin, PhD, MSc, MBBCh to present her seminar entitled "Genetics of Treatment Related Outcomes in Cancer Survivors"

Dr. Sharafeldin is an Assistant Professor of Medicine in the Division of Hematology & Oncology, University of Alabama at Birmingham (UAB), Institute for Cancer Outcomes and Survivorship, and O’Neal Comprehensive Cancer Center. Received training in Medicine and an MSc of Public Health from Faculty of Medicine, Ain Shams University, Egypt; and a PhD in Clinical Epidemiology from University of Pierre and Marie Curie and in Public Health specializing in genetic epidemiology from University of Alberta, Canada. Her research program focuses on the study of genetic architecture of cancer and cancer outcomes; data-driven risk stratification using clinical, social, and genetic factors to identify cancer survivors at risk for adverse outcomes; as well as implementation of interventions to improve treatment-related outcomes in cancer survivors. She is PI on the cTAG and dcTAG studies: randomized controlled interventions to improve cognitive function in cancer survivors; and CAPITAL study: a prospective cohort study to examine the rate of cognitive decline in advanced prostate cancer patients treated with androgen blockers. She co-leads the National Clinical Cohort Collaborative (N3C) Oncology Domain Team examining outcomes in cancer patients using the national N3C EMR-based resource. Her work has been supported by awards from the NCI, Leukemia & Lymphoma Society (LLS) and Be The Match Foundation.